Teva reaches settlements in Nuvigil patent case
JERUSALEM — Teva has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to a patent for Teva’s wakefulness product, Nuvigil (armodafinil) tablets. These settlements dismiss a pending appeal with the United States Court of Appeals for the Federal Circuit of a trial court decision that found the “570 patent” to be valid and infringed.
Teva has reached settlements with each of these companies, granting licenses to allow these parties to market their generic products 180 days after Mylan, the first generic company to file an abbreviated new drug application for the 50 mg, 150 mg, and 250 mg dosages of Nuvigil. The settlements allow Actavis to launch generic 100 mg and 200 mg dosages in June 2016, and the others may launch these dosages 180 days after Actavis in the 100 mg and 200 mg dosage forms. Additional terms of the settlements are agreed by the parties to remain undisclosed.
Previously, Teva settled its patent infringement litigation regarding the 570 patent against Mylan, which allowed Mylan to begin selling generic versions of 50 mg, 150 mg, and 250 mg Nuvigil under license beginning in June 2016, or earlier under certain circumstances.
Hamacher Resource Group’s Dave Wendland to speak at upcoming industry conferences
WAUKESHA, Wis. — The Hamacher Resource Group has announced that Dave Wendland, VP and member of the owners group at Hamacher Resource Group, will be speaking to members of the American Society for Automation in Pharmacy June 27 at their 2014 Midyear conference in Palm Beach, Fla., and on July 21, will speak to independent pharmacists attending McKesson’s IdeaShare conference in Orlando, Fla.
At the ASAP conference Wendland will share the shopper profiles revealed in the 2012 research report "Independent Pharmacy Shoppers: Who, What and Why?" The research was sponsored by the Healthcare Distribution Management Association and details the five shopper types that frequent independent pharmacy. Attendees will understand the types of services that attract these shopper segments and the items that tend to be in their market basket.
At the IdeaShare Conference, Wendland will present a continuing education session, “Customer Loyalty Begins on the Outside,” as well as contribute an audio CE session for those that can’t attend in person, called “Journey to the Center of the Store.” “Customer Loyalty Begins on the Outside,” will provide pharmacists insight into the importance of their building’s exterior and curb appeal in attracting and keeping customers. “Journey to the Center of the Store” will offer tips and tricks to ensure the overall shopping experience inside the store is optimized.
For nearly 35 years, HRG has been serving independent pharmacies and the retail consumer healthcare supply chain by providing merchandising, promotion, planning, sales, and marketing services.
“HRG has deep and broad experience with the independent pharmacy channel and participating in these conferences keeps us in touch with this vital drug store segment,” Wendland stated.
Report: U.S. first in healthcare costs, last in results
NEW YORK — The United States comes in last when it comes to healthcare quality, despite it coming first in spending, according to a new report published Monday by the Commonwealth Fund, a foundation whose goal, according to its website, is "to promote a high-performing healthcare system."
Despite spending $8,508 per person in 2011, the United States ranks poorly in terms of access, efficiency and equity in the healthcare system. Comparatively, the United Kingdom ranked first overall and in most categories, despite spending $3,405 per person — the lowest per capita spending of all the countries covered in the study.
"Americans with below-average incomes were much more likely than their counterparts in other countries to report not visiting a physician when sick; not getting a recommended test, treatment or follow-up care; or not filling a prescription or skipping doses when needed because of costs.
“It is disappointing, but not surprising, that despite our significant investment in health care, the United States has continued to lag behind other countries,” the report’s lead author, Karen Davis, said.
However, the data for the study was all taken before the Affordable Care Act took effect, and the study notes that the ACA might help in terms of making results and access more on-par with cost.
"The U.S. performance on insurance coverage and access to care should begin to improve, particularly for low-income Americans," Davis said. "The Affordable Care Act is also expanding the availability and quality of primary care, which should help all Americans have better care and better health outcomes at lower cost.”